CA2593417C - Method of mutagenesis - Google Patents
Method of mutagenesis Download PDFInfo
- Publication number
- CA2593417C CA2593417C CA2593417A CA2593417A CA2593417C CA 2593417 C CA2593417 C CA 2593417C CA 2593417 A CA2593417 A CA 2593417A CA 2593417 A CA2593417 A CA 2593417A CA 2593417 C CA2593417 C CA 2593417C
- Authority
- CA
- Canada
- Prior art keywords
- mutagenic primer
- parent molecule
- domain
- molecule
- mutagenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 137
- 238000002703 mutagenesis Methods 0.000 title claims abstract description 54
- 231100000350 mutagenesis Toxicity 0.000 title claims abstract description 54
- 230000035772 mutation Effects 0.000 claims abstract description 58
- 231100000219 mutagenic Toxicity 0.000 claims description 180
- 230000003505 mutagenic effect Effects 0.000 claims description 180
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 230000000295 complement effect Effects 0.000 claims description 41
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 32
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 238000000137 annealing Methods 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 238000007792 addition Methods 0.000 claims description 8
- 230000001131 transforming effect Effects 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 108020004638 Circular DNA Proteins 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 4
- 108700005090 Lethal Genes Proteins 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 56
- 108020004414 DNA Proteins 0.000 description 42
- 238000003752 polymerase chain reaction Methods 0.000 description 40
- 239000013612 plasmid Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229960005091 chloramphenicol Drugs 0.000 description 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000005215 recombination Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000002702 ribosome display Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 108091027305 Heteroduplex Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 101150102092 ccdB gene Proteins 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 2
- -1 0.1N NaOH Chemical compound 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- WPJWIROQQFWMMK-UHFFFAOYSA-L beryllium dihydroxide Chemical compound [Be+2].[OH-].[OH-] WPJWIROQQFWMMK-UHFFFAOYSA-L 0.000 description 1
- 229910001865 beryllium hydroxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 238000002742 combinatorial mutagenesis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500417.1 | 2005-01-01 | ||
| US64272905P | 2005-01-10 | 2005-01-10 | |
| US60/642,729 | 2005-01-10 | ||
| GBGB0500417.1A GB0500417D0 (en) | 2005-01-10 | 2005-01-10 | Method of mutagenesis |
| PCT/GB2006/000059 WO2006072801A1 (en) | 2005-01-10 | 2006-01-09 | Method of mutagenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2593417A1 CA2593417A1 (en) | 2006-07-13 |
| CA2593417C true CA2593417C (en) | 2014-10-28 |
Family
ID=35911570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2593417A Expired - Fee Related CA2593417C (en) | 2005-01-10 | 2006-01-09 | Method of mutagenesis |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1844144B1 (pl) |
| JP (2) | JP5789073B2 (pl) |
| AT (1) | ATE464382T1 (pl) |
| AU (1) | AU2006204396B2 (pl) |
| CA (1) | CA2593417C (pl) |
| DE (1) | DE602006013596D1 (pl) |
| DK (1) | DK1844144T3 (pl) |
| ES (1) | ES2343648T3 (pl) |
| GB (1) | GB2421950B (pl) |
| PL (1) | PL1844144T3 (pl) |
| PT (1) | PT1844144E (pl) |
| SI (1) | SI1844144T1 (pl) |
| WO (1) | WO2006072801A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| JP5571567B2 (ja) | 2007-12-21 | 2014-08-13 | メディミューン リミテッド | インターロイキン−４受容体α（ＩＬ−４Ｒα）−１７３に対する結合メンバー |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US20220154170A1 (en) * | 2019-03-01 | 2022-05-19 | Fred Hutchinson Cancer Research Center | Protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817797A (en) * | 1988-06-01 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Sequencing DNA; a modification of the polymerase chain reaction |
| DE4122599C2 (de) * | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| CA2126438C (en) * | 1991-12-24 | 2003-12-02 | Jac A. Nickoloff | Site-directed mutagenesis of dna |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| WO2000058517A1 (en) * | 1999-03-26 | 2000-10-05 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US5789166A (en) * | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| EP1044281B1 (en) * | 1998-01-09 | 2006-11-22 | University Of Utah Research Foundation | Method for in vitro amplification of circular dna |
| ATE465459T1 (de) * | 1999-01-19 | 2010-05-15 | Maxygen Inc | Durch oligonukleotide-vermittelte nukleinsäuren- rekombination |
| JP3859947B2 (ja) * | 2000-08-04 | 2006-12-20 | 独立行政法人理化学研究所 | 突然変異導入方法 |
| US20020155439A1 (en) * | 2000-12-04 | 2002-10-24 | Ana Rodriguez | Method for generating a library of mutant oligonucleotides using the linear cyclic amplification reaction |
-
2006
- 2006-01-09 JP JP2007549952A patent/JP5789073B2/ja not_active Expired - Lifetime
- 2006-01-09 PL PL06701755T patent/PL1844144T3/pl unknown
- 2006-01-09 EP EP06701755A patent/EP1844144B1/en not_active Expired - Lifetime
- 2006-01-09 ES ES06701755T patent/ES2343648T3/es not_active Expired - Lifetime
- 2006-01-09 WO PCT/GB2006/000059 patent/WO2006072801A1/en not_active Ceased
- 2006-01-09 GB GB0600331A patent/GB2421950B/en not_active Expired - Lifetime
- 2006-01-09 PT PT06701755T patent/PT1844144E/pt unknown
- 2006-01-09 SI SI200630689T patent/SI1844144T1/sl unknown
- 2006-01-09 DE DE602006013596T patent/DE602006013596D1/de not_active Expired - Lifetime
- 2006-01-09 CA CA2593417A patent/CA2593417C/en not_active Expired - Fee Related
- 2006-01-09 AU AU2006204396A patent/AU2006204396B2/en not_active Ceased
- 2006-01-09 DK DK06701755.8T patent/DK1844144T3/da active
- 2006-01-09 AT AT06701755T patent/ATE464382T1/de not_active IP Right Cessation
-
2015
- 2015-05-20 JP JP2015102981A patent/JP2015171369A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006072801A1 (en) | 2006-07-13 |
| DE602006013596D1 (de) | 2010-05-27 |
| JP2015171369A (ja) | 2015-10-01 |
| PL1844144T3 (pl) | 2010-09-30 |
| SI1844144T1 (sl) | 2010-07-30 |
| ATE464382T1 (de) | 2010-04-15 |
| EP1844144A1 (en) | 2007-10-17 |
| PT1844144E (pt) | 2010-06-11 |
| JP2008526223A (ja) | 2008-07-24 |
| GB2421950A (en) | 2006-07-12 |
| AU2006204396A1 (en) | 2006-07-13 |
| AU2006204396B2 (en) | 2011-08-11 |
| CA2593417A1 (en) | 2006-07-13 |
| EP1844144B1 (en) | 2010-04-14 |
| GB2421950B (en) | 2007-03-21 |
| DK1844144T3 (da) | 2010-07-19 |
| GB0600331D0 (en) | 2006-02-15 |
| JP5789073B2 (ja) | 2015-10-07 |
| ES2343648T3 (es) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6989250B2 (en) | Method for in vitro molecular evolution of protein function | |
| EP1144616B2 (en) | Method for producing antibody fragments | |
| JP4067516B2 (ja) | ランダムフラグメント化および再組立によるｄｎａ変異誘発 | |
| US20100021477A1 (en) | DESIGN AND GENERATION OF HUMAN DE NOVO pIX PHAGE DISPLAY LIBRARIES | |
| JP2002505845A (ja) | Ｄｎａシャッフリング方法 | |
| EP1131421B1 (en) | Methods for the preparation by in vivo recombination of nucleic acid and polypeptide libraries and uses thereof | |
| JP2015171369A (ja) | 変異誘発方法 | |
| US8518645B2 (en) | Method of mutagenesis | |
| Chetverin | Thirty years of studies of Qβ replicase: What have we learned and what is yet to be learned? | |
| US11001833B2 (en) | Method and kit for generating high affinity binding agents | |
| US20060099611A1 (en) | In vivo affinity maturation scheme | |
| WO2006074765A1 (en) | Molecular biology method | |
| US8728983B2 (en) | Phage display vector | |
| Huovinen | Methods of genetic diversity creation and functional display for directed evolution experiments | |
| HK1060591A (en) | A method for in vitro molecular evolution of protein function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180109 |